These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 8622063

  • 1. Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors.
    Clarke SJ, Hanwell J, de Boer M, Planting A, Verweij J, Walker M, Smith R, Jackman AL, Hughes LR, Harrap KR, Kennealey GT, Judson IR.
    J Clin Oncol; 1996 May; 14(5):1495-503. PubMed ID: 8622063
    [Abstract] [Full Text] [Related]

  • 2. A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors.
    Grem JL, Sorensen JM, Cullen E, Takimoto CH, Steinberg SM, Chen AP, Hamilton JM, Arbuck SG, McAtee N, Lawrence D, Goldspiel B, Johnston PG, Allegra CJ.
    Clin Cancer Res; 1999 Sep; 5(9):2381-91. PubMed ID: 10499608
    [Abstract] [Full Text] [Related]

  • 3. [Phase I study of raltitrexed (ZD-1694)].
    Horikoshi N, Aiba K, Fukuoka M, Akazawa S, Sakata Y, Furuse K, Kanamaru R, Kudoh S, Konishi T, Kurihara M, Niitani H, Furue H, Tsukagoshi S, Taguchi T, Yoshida S, Ota K, Kotake T, Wakui A.
    Gan To Kagaku Ryoho; 1998 Nov; 25(13):2075-84. PubMed ID: 9838910
    [Abstract] [Full Text] [Related]

  • 4. ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group.
    Zalcberg JR, Cunningham D, Van Cutsem E, Francois E, Schornagel J, Adenis A, Green M, Iveson A, Azab M, Seymour I.
    J Clin Oncol; 1996 Mar; 14(3):716-21. PubMed ID: 8622016
    [Abstract] [Full Text] [Related]

  • 5. Phase II study of ZD1694 in patients with advanced gastric cancer.
    Meropol NJ, Pazdur R, Vincent M, Willson JK, Kelsen DP, Douglass HO.
    Am J Clin Oncol; 1996 Dec; 19(6):628-30. PubMed ID: 8931686
    [Abstract] [Full Text] [Related]

  • 6. 'Tomudex' (ZD1694): a novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. 'Tomudex' International Study Group.
    Cunningham D, Zalcberg J, Smith I, Gore M, Pazdur R, Burris H, Meropol NJ, Kennealey G, Seymour L.
    Ann Oncol; 1996 Feb; 7(2):179-82. PubMed ID: 8777175
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumors.
    Rafi I, Boddy AV, Calvete JA, Taylor GA, Newell DR, Bailey NP, Lind MJ, Green M, Hines J, Johnstone A, Clendeninn N, Calvert AH.
    J Clin Oncol; 1998 Mar; 16(3):1131-41. PubMed ID: 9508200
    [Abstract] [Full Text] [Related]

  • 9. Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients.
    Beale P, Judson I, Hanwell J, Berry C, Aherne W, Hickish T, Martin P, Walker M.
    Cancer Chemother Pharmacol; 1998 Mar; 42(1):71-6. PubMed ID: 9619761
    [Abstract] [Full Text] [Related]

  • 10. Clinical and preclinical pharmacokinetics of raltitrexed.
    Clarke SJ, Beale PJ, Rivory LP.
    Clin Pharmacokinet; 2000 Dec; 39(6):429-43. PubMed ID: 11192475
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor.
    Smith I, Jones A, Spielmann M, Namer M, Green MD, Bonneterre J, Wander HE, Hatschek T, Wilking N, Zalcberg J, Spiers J, Seymour L.
    Br J Cancer; 1996 Aug; 74(3):479-81. PubMed ID: 8695369
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer.
    Fizazi K, Ducreux M, Ruffié P, Bonnay M, Daniel C, Soria JC, Hill C, Fandi A, Poterre M, Smith M, Armand JP.
    J Clin Oncol; 2000 Jun; 18(11):2293-300. PubMed ID: 10829050
    [Abstract] [Full Text] [Related]

  • 16. Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2'-deoxyuridine (IdUrd).
    Galanis E, Goldberg R, Reid J, Atherton P, Sloan J, Pitot H, Rubin J, Adjei AA, Burch P, Safgren SL, Witzig TE, Ames MM, Erlichman C.
    Ann Oncol; 2001 May; 12(5):701-7. PubMed ID: 11432631
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies.
    Schwartz GH, Jones CB, Garrison M, Patnaik A, Takimoto C, McCreery H, Skinner M, Tolcher AW, Rowinsky EK.
    Invest New Drugs; 2004 Nov; 22(4):437-48. PubMed ID: 15292714
    [Abstract] [Full Text] [Related]

  • 20. 'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study Group.
    Cunningham D, Zalcberg JR, Rath U, Olver I, Van Cutsem E, Svensson C, Seitz JF, Harper P, Kerr D, Perez-Manga G.
    Eur J Cancer; 1995 Nov; 31A(12):1945-54. PubMed ID: 8562146
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.